represented by the general formula (IV) according to Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination of the above-identified patent application.

The amendments to the claims made in this amendment have been made to delete multiple dependency and have not been made to overcome the prior art, and thus, should be considered to have been made for a purpose unrelated to patentability, and no estoppel should be deemed to attach thereto.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,
N. NISHIKAWA et al.

Leslie J. Paperner Reg No. 33,329

Bruce H. Bernstein
Reg. No. 29,027

October 18, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

P21587.A01

MARKED-UP COPY OF THE CLAIMS

3. (Amended) The compound or the salt thereof according to Claim 1 [or 2], wherein A is a hydrocarbonic ring group represented by the following formula (Ia), (Ib) or (Ic):



(Ia) (Ib) (Ic)

(wherein said rings may have one or more substituents selected from the group consisting of a hydroxyl group, a lower alkyl group, a lower acyl group, a lower alkoxy group and a halogen atom, and wherein the lower alkyl group, the lower acyl group and the lower alkoxy group may have one or more substituents).

4. (Amended) The compound or the salt thereof according to Claim 1 [or 2], wherein A is a benzene ring (wherein said benzene ring may have one or more substituents selected from the group consisting of a hydroxyl group, a lower alkyl group, a lower acyl group, a lower alkoxy group and a halogen atom, and wherein the lower alkyl group, the lower acyl group and the lower alkoxy group may have one or more substituents).

P21587.A01

5. (Amended) The compound or the salt thereof according to [any one of Claims 1 to 4] Claim 1, wherein L is $-NR^3-CO-$ and X is $-NR^5-CO-$ or $-NR^5-SO_2-$.

6. (Amended) The compound or the salt thereof according to [any one of Claims 1 to 4], Claim 1, wherein L is $-CO-NR^3-$ and X is $-NR^5-CO$ or $-NR^5-SO_2-$.

9. (Amended) The compound or the salt thereof according to [Claim 7 or 8] Claim 7, wherein R^{101} is a lower alkyl group (wherein the alkyl group may contain a ring structure, and may have one or more substituents).

10. (Amended) The compound or the salt thereof according to [any one of Claims 7 to 9] Claim 7, wherein R^{103} is an alkyl group having one or more substituents containing one or more hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.

12. (Amended) The compound or the salt thereof according to [any one of Claims 7 to 11] Claim 7, wherein the ring formed by R^{102} and R^{103} bound to each other together with the nitrogen atom to which they bind is a ring represented by the following general formula (XXII):

P21587.A01



(XXII)

[in the formula, X represents $-CH_2-$, -O-, -S-, -NH- or NR^{108}- [in the formula, R^{108} represents a lower alkyl group, a lower acyl group, a phenyl group or a heterocyclic group (wherein the lower alkyl group, the lower acyl group, the phenyl group and the heterocyclic group may have one or more substituents)];

n represents an integer of 1 to 4;

R^{107} represents a hydroxyl group, an amino group, a cyano group, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group (wherein the lower alkyl group, the lower alkoxy group, the lower alkylthio group and the lower alkylcarbonyl group may contain a ring structure, and may have one or more substituents), an aryl group (wherein the aryl group may have one or more substituents) or a heterocyclic group;

m represents an integer of 0 to 4, and when two or more of R^{107} exist, respective R^{107}s are independent and may be the same or different].

14. (Amended) A medicament comprising as an active ingredient a substance selected from the group consisting of the compound according to [any one of Claims 1 to 13]

Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

18. (Amended) The compound according to [any one of Claims 1 to 13] Claim 1 or a physiologically acceptable salt thereof, which is a ligand for neuropeptide Y receptor.

19. (Amended) Use of a substance selected from the group consisting of the compound according to [any one of Claims 1 to 13] Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof for manufacture of [the] a medicament [according to any one of Claims 14 to 16].

20. (Amended) A method for controlling ingestion, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound according to [any one of Claims 1 to 13] Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

21. (Amended) A method for prophylactic and/or therapeutic treatment of a disease in which NPY is involved, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound according to [any one of

Claim 1 to 13] Claim 1 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

24. (Amended) A medicament for controlling ingestion, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 or 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

25. (Amended) A medicament for prophylactic and/or therapeutic treatment of diabetes, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 or 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

26. (Amended) A medicament for prophylactic and/or therapeutic treatment of hypercholesterolemia, hyperlipidemia or arteriosclerosis, which comprises as an active ingredient a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 or 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

P21587.A01

27. (Amended) Use of a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 of 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof for manufacture of [the] a medicament [according to Claims 24 to 26].

28. (Amended) A method for controlling ingestion, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 of 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.

29. (Amended) A method for therapeutic and/or prophylactic treatment of a disease in which NPY is involved, which comprises the step of administering an effective amount of a substance selected from the group consisting of the compound represented by the general formula (IV) according to [Claim 22 or 23] Claim 22 and a physiologically acceptable salt thereof, and a hydrate thereof and a solvate thereof to a mammal including human.